Notable Analyst Rating Changes 04/29: PALM, AKAM, FSLR, AFL Upgraded; AKS, VNDA, CMA Downgraded

UPGRADES
Morgan Joseph upgrades Palm, Inc. (Nasdaq: PALM) from Sell to Hold. Click Here for more color.

Citi upgrades Akamai Technologies Inc (Nasdaq: AKAM) from Hold to Buy, with a price target increased from $32 to $44. Click Here for more color.

First Solar (Nasdaq: FSLR) gets an upgrade from several firms following yesterday's Q110 earnings release:

• BofA/Merrill Lynch from Neutral to Buy;
  
  
• Citi maintains a 'Neutral' rating, and a price target of $135. Click Here for more color;
  
  
• Deutsche Bank upgrades to Buy, price target increased to $155 from $125. Click Here for more color;
  
  
• Baird upgrades from Neutral to Outperform, with a price target increased from $120 to $160; and
  
  
• Soleil Securities upgrades from Sell to Hold. Price target increased from $90 to $117. Click Here for more color.

Aflac (NYSE: AFL) also gets an upgrade from two firms today:

• Citi upgrades from Hold to Buy, a price target increased from $55 to $60. Click Here for more color; and
  
  
• Raymond James upgrades from Outperform to Strong Buy.

For daily real-time Upgrades go to http://www.streetinsider.com/Upgrades

DOWNGRADES
J.P. Morgan downgrades AK Steel (NYSE: AKS) from Overweight to Neutral, and their price target lowered from $27 to $21.

Madison Williams downgrades Vanda Pharmaceuticals (Nasdaq: VNDA) from Buy to Reduce. Price target lowered from $19 to $7.

Rochdale Securities downgrades Comerica (NYSE: CMA) from Neutral to Buy, with their price target increased from $40 to $48.

For daily real-time Downgrades go to http://www.streetinsider.com/downgrades

NEW COVERAGE
Rodman & Renshaw initiates coverage on International Rectifier (NYSE: IRF) with a Market Outperform rating, with a price target of $30.

Wedbush Morgan initiates coverage on three pharma's:

• Amylin Pharmaceuticals (Nasdaq: AMLN) with a Neutral rating and $20 price target. CLick Here for more color;
  
  
• Avanir Pharmaceuticals (Nasdaq: AVNR) with an Outperform rating and $9 price target. Click Here for more color; and
  
  
• Celgene Corp. (Nasdaq: CELG) with an Outperform rating and $73 price target. Click Here for more color

Merriman Curhan Ford initiates coverage on Ballantyne Strong (NYSE: BTN) with a Buy rating. Click Here for more color.

For daily real-time New Coverage go to http://www.streetinsider.com/New+Coverage

You May Also Be Interested In

Create E-mail Alert Related Categories

Special Reports

Related Entities

Deutsche Bank, JPMorgan, Citi, Raymond James, Merrill Lynch, Robert W Baird, Soleil Securities, Bank of America, Wedbush Morgan, Morgan Joseph, Merriman Curhan Ford, Rodman & Renshaw, Notable Analyst Rating Changes

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter